Approval · Notice of Compliance 13522 · 2012
CLARITHROMYCIN: Notice of Compliance 13522
Issued July 30, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13522
- Date
- July 30, 2012
- Company
- Ranbaxy Pharmaceuticals Canada Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Additional product name
- Therapeutic class
- Antibiotic
- Canadian reference product
- BIAXIN BID (Abbott Laboratories Co.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CLARITHROMYCIN | 02390116 | Cancelled Pre Market |
| CLARITHROMYCIN | 02390191 | Cancelled Pre Market |
Medicinal ingredients
- CLARITHROMYCIN 250 MG per TAB
- CLARITHROMYCIN 500 MG per TAB